# Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

> **NCT04150757** · PHASE3 · TERMINATED · sponsor: **Abigail Nixon** · enrollment: 5 (actual)

## Conditions studied

- Sickle Cell Disease
- Vaso-Occlusive Pain Episode in Sickle Cell Disease
- Vaso-occlusive Crisis
- Ketamine
- Intranasal Ketamine
- Analgesia

## Interventions

- **DRUG:** Intranasal ketamine

## Key facts

- **NCT ID:** NCT04150757
- **Lead sponsor:** Abigail Nixon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-19
- **Primary completion:** 2020-10-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Poor recruitment secondary to COVID
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150757, "Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04150757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*